$ARMP Breaking out today possible 200% gain
*****************armata-pharmaceuticals-announces-publication-of-successful-adjunctive-phage-treatment-in-cystic-fibrosis-patient**************
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains
⭐⭐⭐ Sign Up for Free ⭐⭐⭐
1) Download our Mobile App >> link-to.app/dexwirenews
2) Join our Telegram >> t.me/DEXWireNews
3) Sign Up for Text Alerts >>
dexwirenews.com/TEXT
4) Follow @DEXWireNews on Social Media
1) Download our Mobile App >> link-to.app/dexwirenews
2) Join our Telegram >> t.me/DEXWireNews
3) Sign Up for Text Alerts >>
dexwirenews.com/TEXT
4) Follow @DEXWireNews on Social Media
⭐⭐⭐ Sign Up for Free ⭐⭐⭐
1) Download our Mobile App >> link-to.app/dexwirenews
2) Join our Telegram >> t.me/DEXWireNews
3) Sign Up for Text Alerts >>
dexwirenews.com/TEXT
4) Follow @DEXWireNews on Social Media
1) Download our Mobile App >> link-to.app/dexwirenews
2) Join our Telegram >> t.me/DEXWireNews
3) Sign Up for Text Alerts >>
dexwirenews.com/TEXT
4) Follow @DEXWireNews on Social Media
Feragatname
Bilgiler ve yayınlar, TradingView tarafından sağlanan veya onaylanan finansal, yatırım, işlem veya diğer türden tavsiye veya tavsiyeler anlamına gelmez ve teşkil etmez. Kullanım Şartları'nda daha fazlasını okuyun.